Home › Business & Finance › Summit Therapeutics’ stock tumbles again as FDA...
Business & Finance

Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug

Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
Key Points

The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.

The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
FDA (ORG) U.S. (LOCATION)
Originally published by MarketWatch Read original →